众生药业：RAY1225注射液获FDA批准在美国开展II期临床研究，积极寻求国际合作

Core Viewpoint - The company has received FDA approval to conduct Phase II clinical trials for RAY1225, aimed at overweight or obese patients, and is actively seeking international collaboration for multi-center clinical research [1] Group 1 - The company confirmed that RAY1225 injection has been approved by the FDA for Phase II clinical research in the United States [1] - The company is pursuing international cooperation to organize and conduct multi-center clinical studies [1] - The goal is to complete the relevant research as soon as possible and apply for drug approval to provide more treatment options for patients [1]